



Wednesday, March 17, 2021	
<b>Mid-day Session</b>	
12h00-13h30	<b>E-ISFA General Assembly</b> (by invitation only)
13h30-14h30	Lunch symposium by Miltenyi Biotec <b>From AMR to allergy treatment – the diverse value of immunoadsorption</b> Chairs: Andreas Kronbichler, Innsbruck, AT   Wolfgang Ramlow, Rostock, DE
13h30-13h50	<b>Experience in the treatment of AMR with immunoadsorption</b> Christine Kurschat, Cologne, DE
13h50-14h10	<b>Immunoadsorption in ABO-incompatible living kidney transplantation</b> Rolf Weimer, Gießen, DE
14h10-14h30	<b>Extracorporeal IgE immunoadsorption in allergic disease: safety and efficacy</b> Giovanna Leone, Rome, IT
14h30-14h45	Break
14h45-17h00	<b>Plenary session</b> <b>Initiation &amp; apheresis worldwide</b> Chairs: Bernd Hohenstein, Villingen-Schwenningen, DE   Ulrich Julius, Dresden, DE   Andre A. Kaplan, Connecticut, US
14h45-15h05	<b>Welcome and Introduction</b> Andre A. Kaplan, ISFA President, Farmington, US Bernd Hohenstein, E-ISFA President, Villingen-Schwenningen, DE



15h05-15h20	<b>Presidential address</b> <i>Ulrich Julius, Dresden, DE</i>
15h20-15h40	<b>ASFA Guidelines – 35 years of an evidence-based approach</b> <i>Reinhard Klingel, Cologne, DE</i>
15h40-16h00	<b>The 2020 Update to the 2019 ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitis</b> <i>Rasheed Balogun, Charlottesville, US</i>
16h00-16h20	<b>Extracorporeal methods in the Russian Federation: current situation</b> <i>Alexey Sokolov, St. Petersburg, RU</i>
16h20-16h40	<b>Role of Therapeutic Apheresis worldwide</b> <i>Wolfgang Ramlow, Rostock, DE</i>

Evening Session			
<b>Stream 1</b> <b>18h00-20h00</b>	<b>Lipoprotein apheresis I</b> Chairs: <i>Patrick Moriarty, Kansas City, US</i> <i>Peter Grützmacher, Frankfurt, DE</i>	<b>Stream 2</b> <b>18h00-20h00</b>	<b>Extracorporeal Photopheresis (ECP)</b> Chairs: <i>Volker Witt, Vienna, AT</i> <i>Kristina Hölig, Dresden, DE</i>
18h00-18h20	<b>The scientific basis and future of lipoprotein apheresis</b> <i>Gilbert Thompson, London, UK</i>	18h00-18h30	<b>Update on current techniques and mechanisms of action</b> <i>Viola Hähnel, Regensburg, DE</i>
18h20-18h40	<b>Lipoprotein(a) metabolism: <i>in-vivo</i> studies</b> <i>Klaus Parhofer, Munich, DE</i>	18h30-19h00	<b>Role of ECP in graft versus host disease (acute, chronic and prevention)</b> <i>Francis Ayuk Ayuketang, Hamburg, DE</i>

# ISFA – E-ISFA 2021

MARCH 17 – 20, 2021 Virtual congress

JOINT MEETING OF

the 13<sup>th</sup> ISFA World Congress  
and the 3<sup>rd</sup> E-ISFA Congress

18h40-19h00	<b>Mechanisms of clinical benefit of Lipoprotein apheresis in patients with elevated Lipoprotein(a)</b> <i>Tina Khan, London, UK</i>	19h00-19h30	<b>ECP &amp; Solid Organ Transplantation</b> <i>Joseph Schwartz, New York, US</i>
19h00-19h20	<b>Lipoprotein apheresis in severe Hypertriglyceridemia SHTG</b> <i>Wolfgang Ries, Flensburg, DE</i>	19h30-20h00	<b>ECP in pediatric patients</b> <i>Volker Witt, Vienna, AT</i>
19h20-19h40	<b>The impact of long-lasting treatment by lipoprotein apheresis on lipids, inflammatory biomarkers and soluble endoglin</b> <i>Vladimir Blaha, Hradec-Kralove, CZ</i>		
19h40-20h00	<b>Beyond cholesterol – pleiotropic effects of LA</b> <i>Volker J. Schettler, Göttingen, DE</i>		
20h00-20h15	Break		
<b>Stream 1</b> <b>20h15-21h15</b>	<b>New developments</b> Chairs: <i>Sergey N. Pokrovsky, Moscow, RU</i> <i>Bernd Stegmayr, Umea, SE</i>	<b>Stream 2</b> <b>20h15-22h15</b>	<b>Therapeutic apheresis and cellular therapies</b> Chairs: <i>Andrea Jarisch, Frankfurt, DE</i> <i>Kristina Hölig, Dresden, DE</i>
20h15-20h35	<b>ADMA adsorber</b> <i>Roman Rodionov, Dresden, DE</i>	20h15-20h45	<b>CAR-T-Cell-therapies – challenges for apheresis facilities</b> <i>Andrea Jarisch, Frankfurt, DE</i>
20h35-20h55	<b>CRP apheresis prevents ischemic cell death</b> <i>Wolfgang Ries, Flensburg, DE</i>	20h45-21h15	<b>Granulocyte apheresis- is there still a place in current clinical concepts?</b> <i>Kristina Hölig, Dresden, DE</i>



20h55-21h15	<b>Affinity sorbents for therapeutic apheresis</b> <i>Sergey N. Pokrovsky, Moscow, RU</i>	21h15-21h45	<b>Red cell depletion/exchange- clinical application in congenital and acquired diseases</b> <i>Andreas-Michael Brosig, Regensburg, DE</i>
		21h45-22h15	<b>Recent advance in cell adsorption in Japan</b> <i>Yoshihiro Endo, Otsu, JP</i>



**Thursday, March 18, 2021**

**Morning Session**

<b>Stream 1 6h00-8h40</b>	<b>ISFA Session</b> Chairs: Bernd Hohenstein, Villingen-Schwenningen, DE   Wladimir Szpirt, Copenhagen, DK
6h00-6h20	<b>Plaque Regression and Endothelial Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen (PREMIER)</b> <i>Subhash Banerjee, Dallas, US</i>
6h20-6h40	<b>Therapeutic Plasma Exchange (TPE) in the Intensive Care Unit (ICU)</b> <i>Amber P. Sanchez, San Diego, US</i>
6h40-7h00	<b>Influence of Novel Lipid Lowering Drug Developments on Lipoprotein Apheresis Treatment: The Portland Experience</b> <i>Bart Duell, Portland, US</i>
7h00-7h20	<i>Break</i>
7h20-7h40	<b>Efficacy and safety of cytapheresis in elderly patients with ulcerative colitis</b> <i>Yoko Yokoyama, Nishinomiya, JP</i>
7h40-8h00	<b>Efficacy of adsorptive granulocyte/monocyte apheresis in inflammatory bowel disease patients experiencing loss of response to Infliximab</b> <i>Koji Kamikozuru, Nishinomiya, JP</i>
8h00-8h20	<b>First steps toward establishing a lipoprotein apheresis program in India</b> <i>Shamanna Iyengari, New Delhi, IN</i>



8h20-8h40	<b>Bio-inspired dual-functional adsorbent for hemoperfusion therapy of hyperlipidemia</b> <i>Lailiang Ou, Tianjin, CN</i>
<b>Mid-day Session</b>	
12h15-13h15	<b>Abstracts selected for oral presentation</b> Chairs: Jürgen Grässler, Dresden, DE   Lionel Rostaing, Grenoble, FR
12h15-12h30	<b>Repeated lipoprotein apheresis and immune response: Effects on different immune cell populations</b> <i>Romy Walther, Dresden, DE</i>
12h30-12h45	<b>Risk factor constellation of patients with premature cardiovascular events in a lipidology specialty department</b> <i>Ulrike Schatz, Dresden, DE</i>
12h45-13h00	<b>Subtractive Apheresis of Soluble Tumor Necrosis Factor Receptors (sTNFRs) with the LW-02 Immunopheresis Column to Promote Antitumor Activity of Endogenous TNF<math>\alpha</math></b> <i>Robert Segal, California, US</i>
13h00-13h15	<b>Analyses of registry data of patients with anti-GBM and antineutrophil cytoplasmatic (ANCA) antibody-associated vasculitis treated with or without therapeutic apheresis</b> <i>Bernd Stegmayr, Umea, SE</i>
13h30-14h30	Lunch symposium by Fresenius Medical Care <b>Clinical research and practical experience with IA</b> Chairs: Marcus Dörr, Greifswald, DE

# ISFA – E-ISFA 2021

MARCH 17 – 20, 2021 Virtual congress

JOINT MEETING OF

the 13<sup>th</sup> ISFA World Congress  
and the 3<sup>rd</sup> E-ISFA Congress

13h30-13h50	<b>Immune apheresis for the treatment of multiple sclerosis relapses</b> <i>Florian Then Bergh, Leipzig, DE</i>		
13h50-14h10	<b>Immunoadsorption for heart transplantation</b> <i>Cristiano Amarelli, Naples, IT</i>		
14h10-14h30	<b>Multicenter study of immunoadsorption in dilated cardiomyopathy - rationale, design and current status</b> <i>Marcus Dörr, Greifswald, DE</i>		
14h30-14h45	Break		
<b>Stream 1</b> <b>14h45-16h25</b>	<b>Lipoprotein apheresis II</b> Chairs: <i>Volker Schettler, Göttingen, DE</i> <i>Gilbert Thompson, London, UK</i>	<b>Stream 2</b> <b>14h45-16h45</b>	<b>Miscellaneous</b> Chairs: <i>Wolfgang Ramlow, Rostock, DE</i> <i>Yoshihiro Endo, Otsu, JP</i>
14h45-15h05	<b>Difficulties with application of LA</b> <i>Ulrike Schatz, Dresden, DE</i>	14h45-15h15	<b>Apheresis therapy in Thailand – an overview</b> <i>Dusit Lumlertgul, Chiang Mai, TH</i>
15h05-15h25	<b>Lipoprotein apheresis in patients with extremely high Lp(a) and very low LDL-C - effects on the "true" LDL-C</b> <i>Hans-Ulrich Klör, Baunatal, DE</i>	15h15-15h45	<b>Therapeutic apheresis in sepsis and liver failure</b> <i>Steffen Mitzner, Rostock, DE</i>
15h25-15h45	<b>Recent treatment of HoFH in addition of lipoprotein apheresis</b> <i>Mariko Harada-Shiba, Osaka, JP</i>	15h45-16h15	<b>Polystyrene beads adsorbents containing mesopores and linear decapeptide segments as ligands for the removal of <math>\beta</math>2-microglobulin from human plasma</b> <i>Shenqi Wang, Wuhan, CN</i>
15h45-16h05	<b>LA in patients on hemodialysis therapy</b> <i>Wanja Bernhardt, Hanover, DE</i>	16h15-16h45	<b>Therapeutic apheresis in the treatment of autoimmune neuromuscular diseases</b> <i>Sergey Bardakov, St. Petersburg, RU</i>

# ISFA – E-ISFA 2021

MARCH 17 – 20, 2021 Virtual congress

JOINT MEETING OF

the 13<sup>th</sup> ISFA World Congress  
and the 3<sup>rd</sup> E-ISFA Congress

16h05-16h25	<b>Lipoprotein apheresis in older patients – effectiveness and tolerability</b> <i>Sergey Tselmin, Dresden, DE</i>		
<b>Evening Session</b>			
<b>Stream 1</b> <b>18h00-19h40</b>	<b>Lipoprotein apheresis III</b> Chairs: <i>Norbert Weiss, Dresden, DE</i> <i>Mahmoud Barbir, London, UK</i>	<b>Stream 2</b> <b>18h00-19h20</b>	<b>Nephrology and other indications</b> Chairs: <i>Bernd Hohenstein, Villingen-Schwenningen, DE</i> <i>Andreas Kronbichler, Innsbruck, AT</i>
18h00-18h20	<b>LA in Saxony</b> <i>Solveig Frieda Rosa Kuss, Dresden, DE</i>	18h00-18h20	<b>Immunoabsorption in myasthenia gravis</b> <i>Kurt Derfler, Vienna, AT</i>
18h20-18h40	<b>The German Lipoprotein Apheresis Registry (GLAR) – more than 7 years on</b> <i>Volker J. Schettler, Göttingen, DE</i>	18h20-18h40	<b>Successful therapy of a very severe pemphigus vulgaris with rituximab and immunoapheresis</b> <i>Stefanie Heyne, Dresden, DE</i>
18h40-19h00	<b>UK Apheresis Registry</b> <i>Alison Pottle, London, UK</i>	18h40-19h00	<b>Apheresis techniques in order to achieve desensitization before incompatible kidney transplantation</b> <i>Lionel Rostaing, Grenoble, FR</i>
19h00-19h20	<b>Pregnancy in homozygous familial hypercholesterolemia – a case series</b> <i>Milan Blaha, Hradec-Kralove, CZ</i>	19h00-19h20	<b>Actual problems in nephrology taking into account the immunoabsorption</b> <i>Jan Kielstein, Braunschweig, DE</i>
19h20-19h40	<b>LA in children with homozygous FH</b> <i>Christina Taylan, Cologne, DE</i>		





**Friday, March 19, 2021**

**Morning Session**

<b>Stream 1</b> <b>9h45-11h45</b>	<b>Lipidology – Therapy of lipid disorders I</b> Chairs: <i>Elisabeth Steinhagen-Thiessen, Berlin, DE   Ulrich Julius, Dresden, DE</i>
9h45-10h05	<b>Stepwise therapeutic approach to HCH, high Lp(a) and HTG</b> <i>Gerald Klose, Bremen, DE</i>
10h05-10h25	<b>The FH patient registry as the main tool for adequate management of the disease. Experience of Karelia Republic</b> <i>Viktoria Korneva, Petrozavodsk, RU</i>
10h25-10h45	<b>PCSK9 inhibitors</b> <i>Anja Vogt, Munich, DE</i>
10h45-11h05	<b>Bempedoic acid</b> <i>Ulrich Laufs, Leipzig, DE</i>
11h05-11h25	<b>Omega-3 Fatty Acids: doses vs. levels</b> <i>Clemens von Schacky, Munich, DE</i>
11h25-11h45	<b>Inclisiran</b> <i>Ulf Landmesser, Berlin, DE</i>



Mid-day Session		
<b>Stream 1</b> <b>11h45-14h45</b>	<b>Lipidology – Therapy of lipid disorders II</b> Chairs: Hans-Ulrich Klör, Baunatal, DE   Anja Vogt, Munich, DE	
11h45-12h05	<b>Lomitapide</b> Jaimini Cegla, London, UK	
12h05-12h25	<b>Antisense oligonucleotide against ApoCIII</b> Elisabeth Steinhagen-Thiessen, Berlin, DE	
12h25-12h45	<b>CVE in patients with high Lp(a)</b> Katarina Winter, Dresden, DE (Co- and presenting author: Ulrich Julius, Dresden, DE)	
12h45-13h05	Break	
13h05-13h25	<b>Antisense oligonucleotide against Apo(a)</b> Ioanna Gouni-Berthold, Cologne, DE	
13h25-13h45	<b>Evinacumab in HCH</b> Oliver Weingärtner, Jena, DE	
13h45-14h45	<b>Discussion with all session speakers</b>	
	<b>Stream 2</b> <b>14h45-15h45</b>	<b>Role of immunoadsorption in neurology</b> Chairs: Kurt Derfler, Vienna, AT Reinhard Klingel, Cologne, DE

# ISFA – E-ISFA 2021

MARCH 17 – 20, 2021 Virtual congress

JOINT MEETING OF

the 13<sup>th</sup> ISFA World Congress  
and the 3<sup>rd</sup> E-ISFA Congress

		14h45-15h05	<b>Treatment of recurrent hypoglycemias with immunoadsorption – a rare case</b> <i>Bernhard Schmidt, Hanover, DE</i>
		15h05-15h25	<b>Outcome of patients with multiple sclerosis following apheresis therapies</b> <i>Imke Metz, Göttingen, DE</i>
		15h25-15h45	<b>Immunoadsorption in neurological diseases</b> <i>Ingo Kleiter, Bochum, DE</i>
15h45-16h00	Break		
		<b>Stream 2</b> <b>16h00-17h20</b>	<b>Plasma exchange in vasculitis</b> <i>Chairs: Bernd Hohenstein, Villingen-Schwenningen, DE</i> <i>Andreas Kronbichler, Innsbruck, AT</i>
		16h00-16h20	<b>Plasma Exchange in Anca Associated Vaculitits – status quo after PEXIVAS RCT</b> <i>Wladimir Szpirt, Copenhagen, DK</i>
		16h20-16h40	<b>Extracorporeal treatment measures in immune-complex small-vessel vasculitides</b> <i>Andreas Kronbichler, Innsbruck, AT</i>
		16h40-17h00	<b>TPE (Therapeutic Plasma Exchange) for ANCA (Antineutrophil Cytoplasmic Antibody) vasculitis: current status</b> <i>Andre Kaplan, Farmington, US</i>



		17h00-17h20	<b>Immunoglobulin G modifying enzymes – an alternative to plasmapheresis in severe forms of vasculitis?</b> <i>Marten Segelmark, Linköping, SE</i>
<b>Evening Session</b>			
<b>Stream 1</b> 18h00-20h00	<b>Poster Session</b>		
20h00-20h15	Break		
<b>Stream 1</b> 20h15-22h15	<b>COVID-19</b> Chairs: <i>Patrick Moriarty, Kansas City, US</i> <i>Wolfgang Ramlow, Rostock, DE</i>	<b>Stream 2</b> 20h15-21h15	<b>Therapeutic Apheresis in Alzheimer's Disease</b> Chairs: <i>Sandrine Thuret, London, UK</i> <i>Reinhard Klingel, Cologne, DE</i>
20h15-20h35	<b>Plasma Exchange in COVID-19 – is it justified? Based on Covid-Plex RCT</b> <i>Nicholas Carlson, Wladimir Szpirt, Copenhagen, DK</i>	20h15-20h35	<b>Plasma exchange in Alzheimer's Disease</b> <i>Antonio Páez, Barcelona, ES</i>
20h35-20h55	<b>Tba.</b> <i>Patrick Moriarty, Kansas City, US</i>	20h35-20h55	<b>Effect of long-term lipoprotein apheresis on systemic inflammatory state and its potential role in neuroinflammation</b> <i>Jürgen Graessler, Dresden, DE</i>
20h55-21h15	<b>The role of the therapeutic apheresis in the treatment of severe COVID-19 cases</b> <i>Alexey Sokolov, St. Petersburg, RU</i>	20h55-21h15	<b>Apheresis in Alzheimer's Disease</b> <i>Hans Jürgen Grabe, Greifswald, DE</i>



21h15-21h35	<b>Apheresis therapy in COVID-19 patients – insights from LEOSS</b> <i>Bernd Hohenstein, Villingen-Schwenningen, DE</i>		
21h35-21h55	<b>Seraph® 100 Microbind® Adsorber for the treatment of critically ill COVID-19 patients</b> <i>Jan Kielstein, Braunschweig, DE</i>		
21h55-22h15	<b>Cytokine storm targeted therapy on severe COVID-19 patients – artificial liver blood purification system</b> <i>Lan-Juan Li, Hangzhou, CN</i>		



<b>Saturday, March 20, 2021</b>	
<b>Morning Session</b>	
<b>Stream 1</b> <b>9h45-11h45</b>	<b>Interactive discussion: Stroke in patients with high Lp(a) without atherosclerosis</b> Chairs: <i>Ulrike Schatz, Dresden, DE   Mira Katan, Zurich, CH</i>  <i>Mira Katan, Zurich, CH</i> <i>Elisabeth Steinhagen-Thiessen, Berlin, DE</i> <i>Patrick Moriarty, Kansas City, US</i> <i>Ulrike Schatz, Dresden, DE</i> <i>Wanja Bernhardt, Hannover, DE</i> <i>Roman Rodionov, Dresden, DE</i> <i>Ulrich Julius, Dresden, DE</i>
<b>Mid-day Session</b>	
<b>Stream 1</b> <b>12h30-14h30</b>	<b>Interactive discussion: New cardiovascular events during LA therapy</b> Chairs: <i>Ursula Kassner, Berlin, DE   Ulrich Julius, Dresden, DE</i>  <i>Ursula Kassner, Berlin, DE</i> <i>Anja Vogt, Munich, DE</i> <i>Wanja Bernhardt, Hannover, DE</i> <i>Juergen Graessler, Dresden, DE</i> <i>Ulrich Julius, Dresden, DE</i>
14h30-14h45	Break



<b>Stream 1</b> <b>14h45-15h30</b>	<b>Concluding session</b> <i>Chairs: Ulrich Julius, Dresden, DE   Bernd Hohenstein, Villingen-Schwenningen, DE</i>
14h45-15h00	<b>Specific Lp(a) apheresis – best option to treat patients with solo-elevated Lp(a)</b> <i>Sergey N. Pokrovsky, Moscow, RU</i>
15h00-15h15	<b>Cardiologist's perspective on lipoprotein apheresis with case-based discussion</b> <i>Mahmoud Barbir, London, UK</i>
15h15-15h30	<b>Future of lipoprotein apheresis</b> <i>Patrick Moriarty, Kansas City, US</i>